Novartis AG is 174.2x more valuable than Zymeworks Inc. by market capitalization ($293.70 B vs $1.69 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ZYME | NVS |
|---|---|---|
| Market cap | $1.69 B | $293.70 B |
| US-listed rank | #2236 | #46 |
| Revenue (latest FY) | $105.97M | - |
| Net income (latest FY) | -$81.13M | - |
| Net margin | -76.6% | - |
| SEC filings | 324 | 947 |
Novartis AG is 174.2x more valuable than Zymeworks Inc. by market capitalization ($293.70 B vs $1.69 B).
Full pages: Zymeworks Inc. and Novartis AG, or browse the full rankings.